iiCON: Infection Innovation Consortium launched the Liverpool Accelerate Laboratory, a £20 million UK-first high-security facility located at the Liverpool School of Tropical Medicine developed through the consortium, which will accelerate the fight against deadly infections and phase out animal testing.
Published
Signal category
Capital & Finance
Quote
“This £20 million UK-first high-security facility located at Liverpool School of Tropical Medicine and developed through iiCON, will accelerate the fight against deadly infections and help phase out animal testing.”
— iiCON: Infection Innovation Consortium team
Company
iiCON: Infection Innovation Consortium
Saving lives by enabling pioneering infection R&D through industry/academic co-innovation.
- Location
- Liverpool, GB
- Company size
- 8 employees
About iiCON: Infection Innovation Consortium A global collaborative infectious disease R&D programme, iiCON was established in 2020. Founded with government funding provided through UK Research and Innovation’s flagship Strength in Places Fund, it brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation. Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, LifeArc, LYVA Labs, Medicines for Malaria Venture, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON’s eleven specialist research platforms. www.infectioninnovation.com or email: iicon@lstmed.ac.uk